Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab + cemdisiran versus ravulizumab in active paroxysmal nocturnal hemoglobinuria
2020-004486-40Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing Pozelimab + cemdisiran with Ravulizumab control (2 arms). Primary endpoint: Proportion of patients with adequate control of hemolysis. Started Feb 2022; status: active.
02
Drugs
pozelimabcemdisiranravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2020-004486-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004486-40.